|Application ||WB, E|
|Other Accession||NP_060839, 223633999|
|Calculated MW||Predicted: 58 kDa |
Observed: 57 kDa
|Application Notes||DEPDC1B antibody can be used for detection of DEPDC1B by Western blot at 1 - 2 µg/ml.|
|Target/Specificity||DEPDC1B; DEPDC1B antibody is human specific. At least two isoforms are known to exist; this antibody will only detect the largest isoform. DEPDC1B antibody is predicted to not cross-react with DEPDC1A.|
|Reconstitution & Storage||DEPDC1B antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||DEPDC1B Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The DEP domain-containing 1B (DEPDC1B) protein was initially identified as a radiation response biomarker in human lymphoblastoid cell lines (1). Like the related protein DEPDC1A, expression of DEPDC1B correlates with a poor prognosis in cancer patients (2,3). Studies have shown that DEPDC1B levels are upregulated in non-small cell lung cancer (NSCLC) and have an inverse correlation with patient survival. Ectopic expression of DEPDC1B in NSCLC activated Wnt/B-catenin signaling and enhanced cell migration and invasion while silencing DEPDC1B expression suppressed these traits (2).
Niu N, Qin Y, Fridley BL, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 2010; 20:1482-92.
Yang Y, Liu L, Cai J, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/B-catenin signaling. Biochem. Biophys. Res. Commun. 2014; 450:899-905.
Kassambara A, Schoenhals M, Moreaux J, et al. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One 2013; 8:e62752.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.